entertainment -WSS

entertainment

author：leisure time 2025-10-03 00:22:16 - browse：61

Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

Trading in Sarepta shares was halted at $107 with the release of the study results.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Health and fitness trackers are measuring the wrong things

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

FDA's Pazdur wants cancer trials to range beyond China alone

New menopause drug shows promise in relief for hot flashes

hotspot

entertainment

explore

What does generative AI mean for health care? We asked experts

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Drug repurposing or repositioning? The language matters

Ultragenyx gene therapy for rare liver ailment succeeds in late

Continuity nursing helped my family in our darkest PICU moments

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

How to save PrEP access — and even expand it

See how much Covid

explore

DeSantis can now import cheaper drugs. But will Biden get credit?

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Biotech reporter’s notebook: A sunnier mood at JPM 2024

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Woman returns to dialysis after doctors remove transplanted pig kidney

entertainment

knowledge

Wikipedia

hotspot